Feb 7th 2023 - Mar 21st 2023
“Statistically significant improvements in lung fu... See more
Anavex said that the candidate's safety profil... See more
Feb 7th 2023 - Mar 21st 2023
"We believe BCX10013 has the potential to be ... See more
Safety profile is decent.
The Motley Fool Stock Advisor has a track record that speaks for itself, with average recommendations that have returned over 542%*. Act now so you can start investing smarter, not harder.
*As of October 2023$79 is an introductory price for new members only. 60% discount based on the current list price of Stock Advisor of $199/year. Membership will renew annually at the then current list price.“Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission planned for 1H 2023” Oh, 48 weeks! !
Anavex said that the candidate's safety profile also appeared to be relatively good.
Anavex also better in ADAS-Cog14, and far superior safety profile.
>> no clinically significant treatment-related adverse events and no serious adverse events = PERFECT SAFETY PROFILE !!
$AVXL safety profile = excellent !!
with Blarcamesine's outstanding safety profile this will become the #1 off label prescribed drug in the world.
$AVXL for Hans, yes $avxl is great and will get approved when it’s high dose arm absolutely crushes the current SOC with a flawless safety profile.
"We believe BCX10013 has the potential to be a best-in-class treatment option with an oral, once-daily profile,”
Safety profile is decent.
